Valve-in-valve implants via catheter effective in high-risk patients

April 12, 2010

Replacing failing artificial animal-based heart valves by implanting mechanical valves inside them is an effective option for high-risk patients, according to research reported in Circulation: Journal of the American Heart Association.

In the study, physicians from Canada and the United Kingdom describe how 24 high-risk patients whose previous implants failed received transcatheter valve-in-valve implantation, where a new artificial valve is seated within a previously implanted valve made of pig or cow tissue.

The new valve is inserted on a catheter through a small incision between the ribs or through a puncture in a blood vessel in the leg. Placed inside the old surgically implanted valve and expanded by inflating a balloon, the new valve pushes the old one out of the way.

"Once expanded and opened, the new valve opens and functions similarly to the patient's own valve," said John G. Webb, M.D., lead author of the study and Medical Director of Interventional Cardiology and Interventional Research at St. Paul's Hospital in Vancouver, Canada. "The advantage is that failing surgical valves can be replaced without the need for open-heart surgery."

Many, but not all, surgical valves can be replaced this way. "Patients may recover more rapidly, and the concerns about major surgery are reduced," said Webb, who is also a McLeod Family Professor in Valvular Heart Disease Intervention at the University of British Columbia.

The procedure is offered only to selected patients with failed surgical valves who would be poor candidates for another operation. Factors that made the patients in the study risky or ineligible as surgical candidates included two or more prior open-chest surgeries, severe pulmonary hypertension and various heart or other complications.

Although the procedure was first done about five years ago, only isolated cases have been reported on so far, Webb said. The new study presents data from a significant number of patients and involves all four heart valves.

Ten patients in the study had failed aortic valves; seven, failed mitral valves; six, failed pulmonary valves; and one, a failed tricuspid valve.

All patients survived the transcatheter procedure. However, one mitral valve patient whose implantation was converted to traditional open chest surgery suffered a stroke and renal failure and died the next day. Another mitral valve patient died 45 days after the surgery.

While reoperation has been the standard treatment for deteriorated prosthetic valves, such repeat open-heart surgeries can have significant risks, the study authors said. They cite calculations from the Society of Thoracic Surgeons that predict an 80-year-old man with no other health problems faces a 5 percent risk of death for reoperation on an aortic valve, 10 percent risk for a mitral reoperation and more substantial risk if he has other complications.

Almost all of the patients receiving mitral or aortic valve replacements were in their late 70s or 80s. Patients with pulmonary or tricuspid surgical valves were considerably younger. Those patients typically have congenital heart disease and frequently have required multiple surgeries in the past.

"Avoiding yet one more operation is desirable," Webb said.

Most of the patients were men, but he expects the findings would be consistent in women.

Previously implanted valves have many different shapes, sizes and manufacturers -- making it difficult to assess how universally the transcatheter valve implants will function, Webb said.

"The procedure only works well if the original surgical valve is large enough for the new transcatheter valve to fit inside it," he said. "Most surgical valves are large enough, but not all. If the surgical valve is small, the new valve may open more fully than the old valve but not as well as you would like."

Nevertheless, he said, "Generally the transcatheter valves work very well for treating leaky, failed surgical valves."

In an editorial on the research, Blase A. Carabello, M.D., professor and vice-chairman of medicine at Baylor College of Medicine and the Veteran Affairs Medical Center in Houston, Texas, notes that the results focus on the next step in valvular heart disease (VHD) therapy.

"The advent of percutaneous device therapy for VHD is one of the most exciting events in cardiology in the last 50 years, and the work by Webb et al exemplifies the speed with which this technology is advancing."
-end-
Webb's co-authors are: David A. Wood, M.D.; Jian Ye, M.D.; Ronen Gurvitch, M.D.; Jean-Bernard Masson, M.D.; Josep Rodés-Cabau, M.D.; Mark Osten, M.D.; Eric Horlick, M.D.; O. Wendler, M.D.; Eric Dumont, M.D.; Ronald G. Carere, M.D.; Namal Wijesinghe, M.D.; Fabian Nietlispach, M.D.; Mark Johnson, M.D.; Christopher R. Thompson, M.D.; Robert Moss, M.D.; Jonathon Leipsic, M.D.; Brad Munt, M.D.; Samuel V. Lichtenstein, M.D., Ph.D.; and Anson Cheung, M.D. Author disclosures are on the manuscript.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

NR010 - 1062 (Circ/Webb)

American Heart Association

Related Congenital Heart Disease Articles from Brightsurf:

Low risk of COVID-19 infection found among people with congenital heart disease
Results of a retrospective analysis suggest that people born with a heart defect who developed COVID-19 symptoms had a low risk of moderate or severe COVID-19 infection, according to a new article published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.

New method for in utero 4D imaging of baby hearts may aid diagnosis of congenital heart disease
Researchers at King's College London have developed a new method for helping detect congenital heart disease of a baby in pregnant mothers using MRI.

Gout treatment may aid patients with congenital heart disease
A drug used to treat gout, probenecid, may improve heart function in individuals with a particular heart defect, according to results from a small pilot study run by a University of Cincinnati researcher.

Stakeholders update newborn screening guidelines for critical congenital heart disease
A distinguished panel of medical experts, state and federal health officials, and congenital heart disease parent advocates published recommended updates to the current American Academy of Pediatrics' protocol for detecting critical congenital heart disease (CCHD) in newborn babies using pulse oximetry.

Congenital heart disease more deadly in low-income countries
Even though mortality from congenital heart disease (CHD) has declined over the last three decades as diagnosis and treatments have advanced, a new study shows that the chances for a child to survive a CHD diagnosis significantly differs based on the country where he or she is born.

Telehealth effectively diagnoses/manages fetal congenital heart disease in rural patients
A recent study of 368 pregnant mothers, led by Bettina Cuneo, MD, director of perinatal cardiology and fetal cardiac telemedicine at Children's Hospital Colorado, found that fetal congenital heart disease (CHD) was correctly identified and successfully managed according to evidence-based risk stratification.

Uncorrected congenital heart disease may lead to increased risks in pregnant women
Pregnant women with congenital heart disease (CHD) who have not had surgery to repair their cardiac condition are more likely to experience cardiac events or maternal death, especially those with certain conditions in emerging countries, according to a study published Oct.

A new framework to study congenital heart defects
In a new study published in the scientific journal Nature, a team of researchers at the Gladstone Institutes, in collaboration with the University of Luxembourg, reveal for the first time the full spectrum of cells that come together to make a heart at the earliest stages of embryo formation.

Risk of cancer among children, young adults with congenital heart disease
National registry data in Sweden were used in this study that assessed the risk of developing cancer in children and young adults with congenital heart disease compared with healthy people in the general population from birth to age 41.

Congenital heart defects vastly increase risk of heart problems later in life
An infant born with a relatively simple heart defect is far more likely to develop heart problems as an adult, researchers at the Stanford University School of Medicine have discovered.

Read More: Congenital Heart Disease News and Congenital Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.